We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX - Free Report) . Shares have added about 16.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Viking Therapeutics due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Viking Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.
Wider-Than-Expected Q4 Loss, Nil Sales
Viking reported a fourth-quarter 2025 loss of $1.38 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 32 cents in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it has yet to generate revenues.
Quarter in Detail
Research and development expenses amounted to $153.5 million compared with $31.0 million incurred in the year-ago period. This significant rise was primarily due to higher costs associated with clinical studies and increased employee-related expenses.
General and administrative expenses amounted to $11.3 million, down 26% year over year, mainly due to lower costs on legal and patent services.
As of Dec. 31, 2025, Viking Therapeutics had cash and cash equivalents worth $706 million compared with $715 million as of Sept. 30, 2025.
Full-Year 2025 Results
With no marketed products, Viking Therapeutics did not record any revenues during the year.
VKTX reported a loss of $3.19 per share for the full year. In the year-ago period, management reported a loss of $1.01.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -9.11% due to these changes.
VGM Scores
Currently, Viking Therapeutics has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Viking Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Viking Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Illumina (ILMN - Free Report) , a stock from the same industry, has gained 1%. The company reported its results for the quarter ended December 2025 more than a month ago.
Illumina reported revenues of $1.16 billion in the last reported quarter, representing a year-over-year change of +5%. EPS of $1.35 for the same period compares with $0.86 a year ago.
For the current quarter, Illumina is expected to post earnings of $1.06 per share, indicating a change of +9.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Illumina has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Is Viking Therapeutics (VKTX) Up 16.3% Since Last Earnings Report?
It has been about a month since the last earnings report for Viking Therapeutics, Inc. (VKTX - Free Report) . Shares have added about 16.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Viking Therapeutics due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Viking Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late.
Wider-Than-Expected Q4 Loss, Nil Sales
Viking reported a fourth-quarter 2025 loss of $1.38 per share, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 32 cents in the year-ago quarter.
Currently, Viking Therapeutics does not have any approved products in its portfolio. Hence, it has yet to generate revenues.
Quarter in Detail
Research and development expenses amounted to $153.5 million compared with $31.0 million incurred in the year-ago period. This significant rise was primarily due to higher costs associated with clinical studies and increased employee-related expenses.
General and administrative expenses amounted to $11.3 million, down 26% year over year, mainly due to lower costs on legal and patent services.
As of Dec. 31, 2025, Viking Therapeutics had cash and cash equivalents worth $706 million compared with $715 million as of Sept. 30, 2025.
Full-Year 2025 Results
With no marketed products, Viking Therapeutics did not record any revenues during the year.
VKTX reported a loss of $3.19 per share for the full year. In the year-ago period, management reported a loss of $1.01.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
The consensus estimate has shifted -9.11% due to these changes.
VGM Scores
Currently, Viking Therapeutics has a poor Growth Score of F, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Viking Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Viking Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Illumina (ILMN - Free Report) , a stock from the same industry, has gained 1%. The company reported its results for the quarter ended December 2025 more than a month ago.
Illumina reported revenues of $1.16 billion in the last reported quarter, representing a year-over-year change of +5%. EPS of $1.35 for the same period compares with $0.86 a year ago.
For the current quarter, Illumina is expected to post earnings of $1.06 per share, indicating a change of +9.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Illumina has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.